InsightfulValue
← Home

AbbVie
AbbVie

Pharma / Pharma


πŸ”§ Tools

βœ… Due Diligence
πŸ“’ Press Releases

Date Press release
2025-05-30 05:45:00 Levi & Korsinsky Reminds Shareholders Of A Lead Plaintiff Deadline Of June 3, 2025 In Cerevel Therapeutics Holdings, Inc. Lawsuit - Abbv
New york , may 30, 2025 /prnewswire/ -- levi & korsinsky, llp notifies investors in cerevel therapeutics holdings, inc. (’cerevel therapeutics holdings, inc.’ or the ’company’) (nyse: abbv) of a class action securities lawsuit. class definition: the lawsuit seeks to recover losses on behalf of cerevel therapeutics holdings, inc. investors who were adversely affected by alleged securities fraud.
2025-05-29 12:22:00 Contact The Gross Law Firm By June 3, 2025 Deadline To Join Class Action Against Cerevel Therapeutics Holdings, Inc.(abbv)
New york, may 29, 2025 (globe newswire) -- the gross law firm issues the following notice to shareholders of cerevel therapeutics holdings, inc. (nyse: abbv).
2025-05-29 05:45:00 Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (abbv) Seeking Recovery For Investors - Contact The Gross Law Firm
New york , may 29, 2025 /prnewswire/ -- the gross law firm issues the following notice to shareholders of cerevel therapeutics holdings, inc. (nyse: abbv). shareholders who purchased shares of abbv during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
2025-05-27 09:15:00 Lost Money On Cerevel Therapeutics Holdings, Inc. (abbv)? Urged To Join Class Action Before June 3, 2025 - Contact Levi & Korsinsky
New york, ny / access newswire / may 27, 2025 / if you suffered a loss on your cerevel therapeutics holdings, inc. (nyse:abbv) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=150335&wire=1&utm_campaign=22 or contact joseph e. levi, esq.
2025-05-27 09:00:00 Abbvie Features New Data Across Difficult-to-treat Solid Tumors And Blood Cancers At Asco 2025, Highlighting Breadth And Depth Of Its Oncology Portfolio
-Β  Β  key oral presentations highlight new data from abbvie’s novel investigational antibody-drug conjugates (adcs) including telisotuzumab adizutecan (abbv-400, temab-a) in advanced non-small cell lung cancer (nsclc), abbv-706 in high-grade neuroendocrine neoplasms (nens) and pivekimab sunirine (pvek) in blastic plasmacytoid dendritic cell neoplasm (bpdcn). north chicago, ill.
2025-05-27 07:30:00 TGV2aSAmIE tvcnNpbnNr eSBOb3RpZm llcyBDZXJl dmVsIFRoZX JhcGV1dGlj cyBIb2xkaW 5ncywgSW5j LiBJbnZlc3 RvcnMgT2Yg QSBDbGFzcy BBY3Rpb24g TGF3c3VpdC BBbmQgVXBj b21pbmcgRG VhZGxpbmUg LSBBYmJ2
TmV3IHlvcm ssIG55IC8g YWNjZXNzIG 5ld3N3aXJl IC8gbWF5ID I3LCAyMDI1 IC8gaWYgeW 91IHN1ZmZl cmVkIGEgbG 9zcyBvbiB5 b3VyIGNlcm V2ZWwgdGhl cmFwZXV0aW NzIGhvbGRp bmdzLCBpbm MuIChueXNl OmFiYnYpIG ludmVzdG1l bnQgYW5kIH dhbnQgdG8g bGVhcm4gYW JvdXQgYSBw b3RlbnRpYW wgcmVjb3Zl cnkgdW5kZX IgdGhlIGZl ZGVyYWwgc2 VjdXJpdGll cyBsYXdzLC Bmb2xsb3cg dGhlIGxpbm sgYmVsb3cg Zm9yIG1vcm UgaW5mb3Jt YXRpb246IG h0dHBzOi8v emxrLmNvbS 9wc2xyYS0x L2NlcmV2ZW wtdGhlcmFw ZXV0aWNzLW hvbGRpbmdz LWluYy1sYX dzdWl0LXN1 Ym1pc3Npb2 4tZm9ybT9w cmlkPTE1MD I4OSZ3aXJl PTEgb3IgY2 9udGFjdCBq b3NlcGggZS 4gbGV2aSwg ZXNxLg==
2025-05-23 05:45:00 TGV2aSAmIE tvcnNpbnNr eSBOb3RpZm llcyBDZXJl dmVsIFRoZX JhcGV1dGlj cyBIb2xkaW 5ncywgSW5j LiBJbnZlc3 RvcnMgT2Yg QSBDbGFzcy BBY3Rpb24g TGF3c3VpdC BBbmQgVXBj b21pbmcgRG VhZGxpbmUg LSBBYmJ2
TmV3IHlvcm sgLCBtYXkg MjMsIDIwMj UgL3BybmV3 c3dpcmUvIC 0tIGxldmkg JiBrb3JzaW 5za3ksIGxs cCBub3RpZm llcyBpbnZl c3RvcnMgaW 4gY2VyZXZl bCB0aGVyYX BldXRpY3Mg aG9sZGluZ3 MsIGluYy4g KOKAmWNlcm V2ZWwgdGhl cmFwZXV0aW NzIGhvbGRp bmdzLCBpbm Mu4oCZIG9y IHRoZSDigJ ljb21wYW55 4oCZKSAobn lzZTogYWJi dikgb2YgYS BjbGFzcyBh Y3Rpb24gc2 VjdXJpdGll cyBsYXdzdW l0LiBjbGFz cyBkZWZpbm l0aW9uOiB0 aGUgbGF3c3 VpdCBzZWVr cyB0byByZW NvdmVyIGxv c3NlcyBvbi BiZWhhbGYg b2YgY2VyZX ZlbCB0aGVy YXBldXRpY3 MgaG9sZGlu Z3MsIGluYy 4gaW52ZXN0 b3JzIHdoby B3ZXJlIGFk dmVyc2VseS BhZmZlY3Rl ZCBieSBhbG xlZ2VkIHNl Y3VyaXRpZX MgZnJhdWQu
2025-05-22 13:47:00 TGV2aSAmIE tvcnNpbnNr eSBOb3RpZm llcyBTaGFy ZWhvbGRlcn MgT2YgQ2Vy ZXZlbCBUaG VyYXBldXRp Y3MgSG9sZG luZ3MsIElu Yy4gKGFiYn YpIE9mIEEg Q2xhc3MgQW N0aW9uIExh d3N1aXQgQW 5kIEFuIFVw Y29taW5nIE RlYWRsaW5l
TmV3IHlvcm ssIG1heSAy MiwgMjAyNS AoZ2xvYmUg bmV3c3dpcm UpIC0tIGxl dmkgJiBrb3 JzaW5za3ks IGxscCBub3 RpZmllcyBp bnZlc3Rvcn MgaW4gY2Vy ZXZlbCB0aG VyYXBldXRp Y3MgaG9sZG luZ3MsIGlu Yy4gKOKAmW NlcmV2ZWwg dGhlcmFwZX V0aWNzIGhv bGRpbmdzLC BpbmMu4oCZ IG9yIHRoZS DigJljb21w YW554oCZKS AobnlzZTog YWJidikgb2 YgYSBjbGFz cyBhY3Rpb2 4gc2VjdXJp dGllcyBsYX dzdWl0LiBj bGFzcyBkZW Zpbml0aW9u OiB0aGUgbG F3c3VpdCBz ZWVrcyB0by ByZWNvdmVy IGxvc3Nlcy BvbiBiZWhh bGYgb2YgY2 VyZXZlbCB0 aGVyYXBldX RpY3MgaG9s ZGluZ3MsIG luYy4gaW52 ZXN0b3JzIH dobyB3ZXJl IGFkdmVyc2 VseSBhZmZl Y3RlZCBieS BhbGxlZ2Vk IHNlY3VyaX RpZXMgZnJh dWQu
2025-05-22 05:45:00 Q2VyZXZlbC BUaGVyYXBl dXRpY3MgSG 9sZGluZ3Ms IEluYy4gU3 VlZCBGb3Ig U2VjdXJpdG llcyBMYXcg VmlvbGF0aW 9ucyAtIENv bnRhY3QgVG hlIEdyb3Nz IExhdyBGaX JtIEJlZm9y ZSBKdW5lID MsIDIwMjUg VG8gRGlzY3 VzcyBZb3Vy IFJpZ2h0cy AtIEFiYnY=
TmV3IHlvcm sgLCBtYXkg MjIsIDIwMj UgL3BybmV3 c3dpcmUvIC 0tIHRoZSBn cm9zcyBsYX cgZmlybSBp c3N1ZXMgdG hlIGZvbGxv d2luZyBub3 RpY2UgdG8g c2hhcmVob2 xkZXJzIG9m wqBjZXJldm VsIHRoZXJh cGV1dGljcy Bob2xkaW5n cywgaW5jLi AobnlzZTog YWJidikuIH NoYXJlaG9s ZGVycyB3aG 8gcHVyY2hh c2VkIHNoYX JlcyBvZiBh YmJ2IGR1cm luZyB0aGUg Y2xhc3MgcG VyaW9kIGxp c3RlZCBhcm UgZW5jb3Vy YWdlZCB0by Bjb250YWN0 IHRoZSBmaX JtIHJlZ2Fy ZGluZyBwb3 NzaWJsZSBs ZWFkIHBsYW ludGlmZiBh cHBvaW50bW VudC4=
2025-05-21 13:20:00 Q2VyZXZlbC BUaGVyYXBl dXRpY3MgSG 9sZGluZ3Ms IEluYy4gU3 VlZCBGb3Ig U2VjdXJpdG llcyBMYXcg VmlvbGF0aW 9ucyAtIENv bnRhY3QgVG hlIEdyb3Nz IExhdyBGaX JtIEJlZm9y ZSBKdW5lID MsIDIwMjUg VG8gRGlzY3 VzcyBZb3Vy IFJpZ2h0cy DigJMgQWJi dg==
TmV3IHlvcm ssIG1heSAy MSwgMjAyNS AoZ2xvYmUg bmV3c3dpcm UpIC0tIHRo ZSBncm9zcy BsYXcgZmly bSBpc3N1ZX MgdGhlIGZv bGxvd2luZy Bub3RpY2Ug dG8gc2hhcm Vob2xkZXJz IG9mIGNlcm V2ZWwgdGhl cmFwZXV0aW NzIGhvbGRp bmdzLCBpbm MuIChueXNl OiBhYmJ2KS 4=
2025-05-21 07:25:00 U2hhcmVob2 xkZXJzIFRo YXQgTG9zdC BNb25leSBP biBDZXJldm VsIFRoZXJh cGV1dGljcy BIb2xkaW5n cywgSW5jLi hhYmJ2KSBV cmdlZCBUby BKb2luIENs YXNzIEFjdG lvbiAtIENv bnRhY3QgTG V2aSAmIEtv cnNpbnNreS BUbyBMZWFy biBNb3Jl
TmV3IHlvcm ssIG55IC8g YWNjZXNzIG 5ld3N3aXJl IC8gbWF5ID IxLCAyMDI1 IC8gaWYgeW 91IHN1ZmZl cmVkIGEgbG 9zcyBvbiB5 b3VyIGNlcm V2ZWwgdGhl cmFwZXV0aW NzIGhvbGRp bmdzLCBpbm MuIChueXNl OmFiYnYpIG ludmVzdG1l bnQgYW5kIH dhbnQgdG8g bGVhcm4gYW JvdXQgYSBw b3RlbnRpYW wgcmVjb3Zl cnkgdW5kZX IgdGhlIGZl ZGVyYWwgc2 VjdXJpdGll cyBsYXdzLC Bmb2xsb3cg dGhlIGxpbm sgYmVsb3cg Zm9yIG1vcm UgaW5mb3Jt YXRpb246IG h0dHBzOi8v emxrLmNvbS 9wc2xyYS0x L2NlcmV2ZW wtdGhlcmFw ZXV0aWNzLW hvbGRpbmdz LWluYy1sYX dzdWl0LXN1 Ym1pc3Npb2 4tZm9ybT9w cmlkPTE0OT Q4NSZ3aXJl PTEgb3IgY2 9udGFjdCBq b3NlcGggZS 4gbGV2aSwg ZXNxLg==
2025-05-20 05:45:00 U2hhcmVob2 xkZXJzIFRo YXQgTG9zdC BNb25leSBP biBDZXJldm VsIFRoZXJh cGV1dGljcy BIb2xkaW5n cywgSW5jLi hhYmJ2KSBT aG91bGQgQ2 9udGFjdCBM ZXZpICYgS2 9yc2luc2t5 IEFib3V0IF BlbmRpbmcg Q2xhc3MgQW N0aW9uIC0g QWJidg==
TmV3IHlvcm sgLCBtYXkg MjAsIDIwMj UgL3BybmV3 c3dpcmUvIC 0tIGxldmkg JiBrb3JzaW 5za3ksIGxs cCBub3RpZm llcyBpbnZl c3RvcnMgaW 4gY2VyZXZl bCB0aGVyYX BldXRpY3Mg aG9sZGluZ3 MsIGluYy4g KOKAmWNlcm V2ZWwgdGhl cmFwZXV0aW NzIGhvbGRp bmdzLCBpbm Mu4oCZIG9y IHRoZSDigJ ljb21wYW55 4oCZKSAobn lzZTogYWJi dikgb2YgYS BjbGFzcyBh Y3Rpb24gc2 VjdXJpdGll cyBsYXdzdW l0LiBjbGFz cyBkZWZpbm l0aW9uOiB0 aGUgbGF3c3 VpdCBzZWVr cyB0byByZW NvdmVyIGxv c3NlcyBvbi BiZWhhbGYg b2YgY2VyZX ZlbCB0aGVy YXBldXRpY3 MgaG9sZGlu Z3MsIGluYy 4gaW52ZXN0 b3JzIHdoby B3ZXJlIGFk dmVyc2VseS BhZmZlY3Rl ZCBieSBhbG xlZ2VkIHNl Y3VyaXRpZX MgZnJhdWQu
2025-05-19 13:30:00 TGV2aSAmIE tvcnNpbnNr eSBBbm5vdW 5jZXMgVGhl IEZpbGluZy BPZiBBIFNl Y3VyaXRpZX MgQ2xhc3Mg QWN0aW9uIE 9uIEJlaGFs ZiBPZiBDZX JldmVsIFRo ZXJhcGV1dG ljcyBIb2xk aW5ncywgSW 5jLiAoYWJi dikgU2hhcm Vob2xkZXJz
TmV3IHlvcm ssIG1heSAx OSwgMjAyNS AoZ2xvYmUg bmV3c3dpcm UpIC0tIGxl dmkgJiBrb3 JzaW5za3ks IGxscCBub3 RpZmllcyBp bnZlc3Rvcn MgaW4gY2Vy ZXZlbCB0aG VyYXBldXRp Y3MgaG9sZG luZ3MsIGlu Yy4gKOKAmW NlcmV2ZWwg dGhlcmFwZX V0aWNzIGhv bGRpbmdzLC BpbmMu4oCZ IG9yIHRoZS DigJljb21w YW554oCZKS AobnlzZTog YWJidikgb2 YgYSBjbGFz cyBhY3Rpb2 4gc2VjdXJp dGllcyBsYX dzdWl0Lg==
2025-05-19 13:04:00 U2hhcmVob2 xkZXJzIFRo YXQgTG9zdC BNb25leSBP biBDZXJldm VsIFRoZXJh cGV1dGljcy BIb2xkaW5n cywgSW5jLi hhYmJ2KSBT aG91bGQgQ2 9udGFjdCBU aGUgR3Jvc3 MgTGF3IEZp cm0gQWJvdX QgUGVuZGlu ZyBDbGFzcy BBY3Rpb24g LSBBYmJ2
TmV3IHlvcm sgLCBtYXkg MTksIDIwMj UgL3BybmV3 c3dpcmUvIC 0twqB0aGUg Z3Jvc3MgbG F3IGZpcm0g aXNzdWVzIH RoZSBmb2xs b3dpbmcgbm 90aWNlIHRv IHNoYXJlaG 9sZGVycyBv ZsKgY2VyZX ZlbCB0aGVy YXBldXRpY3 MgaG9sZGlu Z3MsIGluYy 4gKG55c2U6 IGFiYnYpLi BzaGFyZWhv bGRlcnMgd2 hvIHB1cmNo YXNlZCBzaG FyZXMgb2Yg YWJidiBkdX JpbmcgdGhl IGNsYXNzIH BlcmlvZCBs aXN0ZWQgYX JlIGVuY291 cmFnZWQgdG 8gY29udGFj dCB0aGUgZm lybSByZWdh cmRpbmcgcG 9zc2libGUg bGVhZCBwbG FpbnRpZmYg YXBwb2ludG 1lbnQu
2025-05-19 07:30:00 U2hhcmVob2 xkZXJzIFRo YXQgTG9zdC BNb25leSBP biBDZXJldm VsIFRoZXJh cGV1dGljcy BIb2xkaW5n cywgSW5jLi hhYmJ2KSBT aG91bGQgQ2 9udGFjdCBM ZXZpICYgS2 9yc2luc2t5 IEFib3V0IF BlbmRpbmcg Q2xhc3MgQW N0aW9uIC0g QWJidg==
TmV3IHlvcm ssIG55IC8g YWNjZXNzIG 5ld3N3aXJl IC8gbWF5ID E5LCAyMDI1 IC8gaWYgeW 91IHN1ZmZl cmVkIGEgbG 9zcyBvbiB5 b3VyIGNlcm V2ZWwgdGhl cmFwZXV0aW NzIGhvbGRp bmdzLCBpbm MuIChueXNl OmFiYnYpIG ludmVzdG1l bnQgYW5kIH dhbnQgdG8g bGVhcm4gYW JvdXQgYSBw b3RlbnRpYW wgcmVjb3Zl cnkgdW5kZX IgdGhlIGZl ZGVyYWwgc2 VjdXJpdGll cyBsYXdzLC Bmb2xsb3cg dGhlIGxpbm sgYmVsb3cg Zm9yIG1vcm UgaW5mb3Jt YXRpb246IG h0dHBzOi8v emxrLmNvbS 9wc2xyYS0x L2NlcmV2ZW wtdGhlcmFw ZXV0aWNzLW hvbGRpbmdz LWluYy1sYX dzdWl0LXN1 Ym1pc3Npb2 4tZm9ybT9w cmlkPTE0OT EyNyZ3aXJl PTEgb3IgY2 9udGFjdCBq b3NlcGggZS 4gbGV2aSwg ZXNxLg==
AbbVie

πŸ“° Browse additional press releases for AbbVie!

Sign up for free or log in

πŸš€ Don’t miss "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free!

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal